echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Lancet Oncol: Pratinib is expected to be used in the treatment of non-small cell lung cancer with positive RET fusion (ARROW trial)

    Lancet Oncol: Pratinib is expected to be used in the treatment of non-small cell lung cancer with positive RET fusion (ARROW trial)

    • Last Update: 2021-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The carcinogenic changes of RET have been found in a variety of tumor types, including 1-2% of non-small cell lung cancer (NSCLC)
    .
    We aim to evaluate the safety, tolerability and anti-tumor activity of Palaxitinib.
    Palaxitinib is a potent oral selective RET inhibitor for patients with RET fusion-positive NSCLC

    .
    The purpose of this study was to evaluate the safety, tolerability and anti-tumor activity of pratinib (Pralsetinib, a highly effective, oral, and selective RET inhibitor) in patients with RET fusion-positive NSCLC

    .
    The ARROW trial is a multi-cohort, open-label Phase 1/2 study conducted at 71 locations in 12 countries, recruiting patients with locally advanced or metastatic solid tumors over 18 years of age, including NSCLC with RET fusion-positive NSCLC Patient

    .
    Include patients with locally advanced or metastatic solid tumors 18 years of age or older, including RET fusion-positive NSCLC, and the performance status of the Eastern Cooperative Oncology Group 0-2 (later restricted to 0- in the protocol revision 1) In the second phase, the patient is treated with 400 mg of pratinib orally every day until the disease progresses, intolerance, withdrawal from the trial or the investigator's decision

    .
    The primary endpoint is the overall response rate (according to the version 1.
    1 of the solid tumor response evaluation standard and evaluated by a blinded independent center review) and safety

    .
    To evaluate the tumor response of RET fusion-positive NSCLC patients.
    .
    .



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.